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Abstract
Although Candida albicans (CA) is the most common cause of Candida bloodstream infections (BSIs), recent studies have observed an
increasing percentage of candidaemias caused by non-albicans Candida species (NAC). In the present study, we attempted to identify the
predictors of candidaemia due to NAC compared to CA. We analyzed data from an active population-based surveillance in Barcelona
(Spain) from January 2002 to December 2003. Factors associated with NAC fungaemia were determined by multivariate analysis. A total
of 339 episodes of Candida BSI, in 336 patients (median age 63 years, interquartile range: 41–72 years), were included. CA was the most
commonly isolated (52%), followed by Candida parapsilosis (23%), Candida tropicalis (10%), Candida glabrata (8.6%), Candida krusei (3.4%)
and other NAC spp. (3%).Overall, 48% of cases were due to NAC spp. Multivariate logistic regression analysis identiﬁed factors associ-
ated with a risk of BSI due to NAC spp.: having received a haematologic transplant (OR 10.8; 95% CI 1.31–90.01; p 0.027), previous
ﬂuconazole exposure (OR 4.47; 95% CI 2.12–9.43; p <0.001) and neonatal age (OR 4.42; 95% CI 1.63–12.04; p 0.004). Conversely, pre-
vious CA colonization (OR 0.33; 95% CI 0.19–0.57; p 0.001) and previous antibiotic use (OR 0.42; 95% CI 0.21–0.85; p 0.017) were
associated with CA fungaemia compared to NAC. In conclusion, NAC candidaemia comprised 48% of cases in our series. Predictors of
NAC include having received a haematologic transplant, neonatal age and previous ﬂuconazole use.
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Introduction
Candida species accounted for 8–10% of all nosocomial
bloodstream infections (BSIs) in the USA during the 1990s
and were considered the fourth leading cause of nosocomial
BSI [1,2]. Although Candida albicans (CA) continues to be
the most common cause of Candida BSI, longitudinal studies
have detected an increase of other Candida species in this
condition [3–6]. Non-albicans Candida species (NAC) cur-
rently account for approximately half of all cases of candida-
emia, although there is little published information on the
factors associated with the increase in NAC candidaemia
[4,5,7–10].
The changing epidemiology of Candida BSI has generated
concern about the emergence of azole drug resistance and its
clinical relevance [5,9,11]. Although CA is generally suscepti-
ble to ﬂuconazole, Candida glabrata, the second cause of can-
didaemia in the USA, shows decreased susceptibility to this
agent in up to 65% of cases [10–12]. The emergence of
azole-resistant strains and the discovery of new antifungal
drugs (new triazoles and echinocandins) have raised impor-
tant questions about the use of ﬂuconazole as a ﬁrst-line
drug. Therefore, it is of great value to identify the risk factors
that distinguish CA infections from those due to NAC to aid
clinicians in choosing an empiric anti-Candida therapy [13].
Various studies in immunocompromised and intensive care
unit (ICU) patients with candidaemia have examined the clini-
cal features that differentiate CA infection from NAC infec-
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tion; however, the predictors of NAC BSI have not been
prospectively studied in a general patient population [3,14–
16]. The present study aimed to identify the risk factors
associated with fungaemia due to NAC species compared to
CA in a general patient population in the hope that this
information can be used to guide the initial empiric therapy.
Materials and Methods
Study and study population
We conducted a prospective, population-based active sur-
veillance for Candida BSI in the Barcelona (Spain) area (popu-
lation, 3.9 million), between 1 January 2002 and 31
December 2003. Fourteen major institutions participated,
ranging in size from 214 to 1200 beds. A case was deﬁned as
the incident isolation of any Candida species from the blood
of a surveillance area resident. Candidaemia episodes that
occurred >30 days after the initial case were considered a
new episode. Patients with candidaemia caused simulta-
neously by different species of Candida were excluded from
the analysis because they had both CA and NAC species.
Data collection
The case report was laboratory-based. All blood cultures in
which a Candida species had been isolated were reported to
the study coordinator (DR). The coordinator visited the hos-
pital to conﬁrm the infection, completed the case report
form, and recorded the outcome. The clinical laboratories
were periodically audited to ensure that all cases of candida-
emia were reported. A standardized case report form was
used to abstract the medical records. The data collected
included patient demographic characteristics; comorbid
conditions; concomitant infections; previous Candida coloni-
zation; exposure to antibiotic, antifungal and immunosuppres-
sive therapy; total parenteral nutrition received; surgical
procedures; central venous catheter (CVC) use; haemo-
dialysis; mechanical ventilation; treatment of candidaemia and
outcome.
To measure disease severity, we used the Acute Physiol-
ogy and Chronic Health Evaluation II score [17] for adult
patients admitted to ICUs and the Karnofsky performance
status scale for adults outside the ICU [18]. No standardized
paediatric severity of illness score was used. Risk factors
were assessed within 30 days prior to the diagnosis by posi-
tive sample.
Microbiological methods
Candida detection and species identiﬁcation were performed
at the participating laboratories according to their standard
protocols. Isolates were sent to the Mycology Reference
Laboratory (MRL), National Center for Microbiology,
Madrid, Spain, for species conﬁrmation and antifungal suscep-
tibility testing, using standard morphological and physiological
methods, including fermentation of and growth on carbon
sources, growth on nitrogen sources and growth at various
temperatures. Candida parapsilosis ATCC 22019 and Candida
krusei ATCC 6258 were used as quality control organisms
for antifungal drug susceptibility testing [12]. When MRL and
submitting laboratory identiﬁcations differed, the MRL identi-
ﬁcation was used for the study. MICs of ﬂuconazole and vo-
riconazole were determined by the broth microdilution
method as recommended by the European Committee on
Antimicrobial Susceptibility Testing (EUCAST). Interpretive
breakpoints proposed by EUCAST for ﬂuconazole and voric-
onazole resistance are >4 and >0.12 mg/L, respectively [19].
Statistical analysis
Population incidences of CA and NAC were calculated using
denominator data obtained from the 2001 local census. Sta-
tistical analyses were performed using SPSS software, version
15.0 (SPSS Inc., Chicago, IL, USA). The results for categorical
variables are expressed as a percentage, and numerical data
are expressed as the mean (SD), median, and interquartile
range for ages. The chi-square test or Fisher’s exact test
(two-tailed) were used to compare categorical variables, and
an unpaired Student’s t-test was used for continuous vari-
ables. Multivariate stepwise logistic regression analysis was
carried out to identify predictors of candidaemia due to
NAC. p <0.05 was considered statistically signiﬁcant in the
multivariate modeling.
Results
During the study period, 345 cases of Candida BSI were
detected. Six episodes of polyfungal candidaemia were
excluded, leaving 339 episodes in 336 patients (median age
63 years, interquartile range: 41–72 years). A total of 176
(52%) patients had fungaemia due to C. albicans and 163
(48%) had infection due to NAC. The average annual inci-
dence of candidaemia was 4.3 cases per 100 000 population
(2.2 cases per 100 000 population for CA and 2.1 cases per
100 000 population for NAC). Demographics, clinical charac-
teristics, underlying comorbid conditions and the outcome of
patients with NAC BSI compared to those with CA BSI are
summarized in Table 1.
The NAC species isolated included 78 C. parapsilosis
(23%), 34 Candida tropicalis (10%), 29 Candida glabrata (8.6%),
12 C. krusei (3.6%), three Candida kefyr (0.9%), two Candida
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lusitaniae (0.6%), two Candida guilliermondii (0.6%), one
Candida famata (0.3%), one Candida inconspicua (0.3%) and
one Candida norvegensis (0.3%). Percentages of in vitro ﬂuco-
nazole and voriconazole resistance among the 339 incident
bloodstream isolates of Candida spp. are shown in Table 2.
Subgroup analysis for speciﬁc Candida spp. showed that
patients with C. albicans fungaemia were admitted more often
to surgical wards (25% CA vs. 13.5% NAC; p 0.008), had dia-
betes mellitus (25% CA vs. 16% NAC; p 0.03) or chronic
renal failure (41.5% CA vs. 27.2% NAC; p 0.006) and had
been previously colonized with C. albicans (42.3% CA vs.
20.9% NAC; p <0.001). Cases with C. parapsilosis were more
likely to be infants (28% vs. 5%; p <0.001) and have an
indwelling CVC (97% vs. 87%; p 0.006), and less likely to die
within 30 days (23% vs. 45%; p 0.001) compared to the
other cases. C. krusei cases had received previous ﬂuconazole
(75% vs. 14%; p <0.001) and immunosuppressive therapy
(75% vs. 38%; p 0.01) more often, were more frequently
neutropaenic (67% vs. 9%; p <0.001) and had haematological
malignancies (58% vs. 12%; p <0.001) more often than
non-krusei cases. C. tropicalis cases were also likely to be
neutropaenic (24% vs. 10%; p 0.04), have haematological
malignancies (29% vs. 11%; p 0.007), and die within 30 days
(56% vs. 38%), although this latter difference did not reach
statistical signiﬁcance (p 0.06). Overall mortality tended to
be lower in patients with NAC BSI compared to CA BSI,
although this trend did not reach statistical signiﬁcance
(36.8% NAC vs. 42.6% CA; p 0.27).
Factors associated with NAC fungaemia were determined
by univariate analysis (Table 1) and multivariate analysis
TABLE 1. Demographics, epidemiological data and clinical
characteristics of the patients included in the present study
Characteristics
(n = 339 episodes in
336 patients)
C. albicans,
n = 176
(52%)
Non-albicans
Candida spp.,
n = 163 (48%) p
Age (years), mean (SD) 57.9 (24.07) 47.7 (27.45) 0.011
Elderly (>65 years) 95 (54) 66 (40.5) 0.013
Male sex 101 (57.4) 98 (60.1) 0.659
Nosocomial candidaemia 158 (89.8) 149 (91.4) 0.573
Prior hospitalizationa 86 (48.9) 77 (47.2) 0.770
APACHE II (severity high)b 29 (26.9) 20 (19) 0.176
Length of stay before
candidaemia (days), mean (SD)
30.1 (35.3) 29.7 (33.6) 0.752
Location of the patients
Medical ward 49 (27.8) 64 (39.3) 0.026
Surgical ward 44 (25) 22 (13.5) 0.008
ICU hospitalization (except neonates) 52 (29.5) 37 (22.7) 0.152
Neonatal ICU hospitalizationc 7 (4) 17 (10.4) 0.032
Pediatric ward (excluding neonates) 7 (4) 9 (5.5) 0.611
Outpatient 17 (9.7) 14 (8.6) 0.851
Predisposing factorsd
Diabetes mellitus 44 (25) 26 (16) 0.037
Chronic renal failure 73 (41.5) 44 (27.0) 0.006
Solid tumour 45 (25.6) 27 (16.6) 0.043
Haematological malignancy 16 (9.1) 32 (19.6) 0.005
Neutropaenia 11 (6.3) 28 (17.2) 0.002
Solid organ transplant recipient 2 (1.1) 8 (4.9) 0.054
Haematological transplant recipient 1 (0.6) 15 (9.2) <0.001
Surgery in previous 3 months 85 (48.3) 69 (4236) 0.271
Prior immunosuppressive drugse 66 (37.5) 66 (40.5) 0.479
Prior antibiotics (1 previous month) 158 (89.8) 137 (84.0) 0.146
Prior ﬂuconazole therapy 12 (6.8) 41 (25.2) <0.001
CVC placement 130 (73.9) 138 (84.7) 0.015
Total parenteral nutrition 57 (32.4) 67 (41.1) 0.096
Previous Candida colonizationf 74 (42.0) 34 (20.9) <0.001
Candiduria due to Candida albicans 36 (20.5) 12 (7.4) 0.001
Portal of entry
Primary candidaemia 105 (59.7) 95 (58.3) 0.797
CVC-related candidaemia 54 (30.7) 53 (32.5) 0.717
Secondary candidaemia 17 (9.7) 15 (9.2) 1
Optimal antifungal treatmentg 82 (52.2) 86 (52.8) 0.36
Outcome
Shock 46 (26.1) 43 (26.4) 0.967
Mechanical ventilation 55 (31.3) 46 (28.2) 0.592
ICU admission during outcome 15 (8.5) 10 (6.1) 0.533
Acute renal failure 37 (21.0) 26 (16.0) 0.242
Early mortality (<7 days) 47 (26.7) 35 (21.5) 0.261
Overall mortality (<30 days) 75 (42.6) 60 (36.8) 0.275
Categorical variables are expressed as total number and percentages, and
numerical data are expressed as the mean and standard deviation (SD).
aPatients hospitalized within 3 months prior to candidaemia.
APACHE, Acute Physiology and Chronic Health Evaluation score system.
bIncludes patients with APACHE >20 (only patients admitted to ICU).
ICU, intensive care unit.
cNAC in the neonatal ICU were due to Candida parapsilosis in 16 cases and
Candida glabrata in one case.
dSome patients had more than one predisposing factor.
eIncludes corticoids, chemotherapy, and other immunosuppressive drugs.
CVC, central venous catheter.
fPrevious Candida colonization due to the same Candida spp. that caused candi-
daemia (includes candiduria).
gDeﬁned as at least 5 days of adequate antifungal treatment.
TABLE 2. Species distribution and in vitro susceptibilities to
ﬂuconazole and voriconazole (European Committee on
Antimicrobial Susceptibility Testing breakpoint for Candida
susceptibilitya)
Species
Fluconazole resistant
isolates/n total
isolates (%)
Voriconazole resistant
isolates/n total
isolates (%)
Candida albicans 2/176 (1.1) 1/176 (0.6)
Candida parapsilosis 2/78 (2.6) 2/78 (2.6)
Candida tropicalis 1/34 (2.9) 1/34 (2.9)
Candida glabrata 13/29 (44.8) 19/29 (65.5)
Candida krusei 12/12 (100) 12/12 (100)
Candida kefyr 0/3 (0) 0/3 (0)
Candida lusitaniae 0/2 (0) 0/2 (0)
Candida guillierrmondii 0/2 (0) 0/2 (0)
Candida famata 1/1 (100) 1/1 (100)
Candida inconspicua 1/1 (100) 0/1 (0)
Candida norvegensis 1/1 (100) 1/1 (100)
Total 33/339 (9.7) 37/339 (11)
aFluconazole-resistant isolates: MIC >4 mg/L.
Voriconazole-resistant isolates: MIC >0.12 mg/L.
TABLE 3. Multivariate analysis of risk factors associated
with non-albicans Candida infection among all patients with
candidaemia
Variable OR 95% CI p
Haematological transplant recipient 10.8 1.31–90.01 0.027
Previous ﬂuconazole usea 4.47 2.12–9.43 <0.001
Neonatal intensive care unit admission 4.42 1.63–12.04 0.004
Previous antibiotic useb 0.42 0.21–0.85 0.017
Previous Candida albicans colonization 0.33 0.19–0.57 <0.001
aAt least 3 days of ﬂuconazole treatment within 30 days prior to candidaemia.
bAt least 3 days of any antibiotic treatment within 30 days prior to candidaemia.
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(Table 3). In the multivariate analysis, the fact of having
undergone haematological transplantation (OR 10.8; 95% CI
1.31–90.1; p 0.027) or previous exposure to ﬂuconazole (OR
4.47; 95% CI 2.12–9.43; p <0.001), and neonatal age (OR
4.42; 95% CI 1.63–12.04; p 0.004) were signiﬁcantly associ-
ated with NAC fungaemia, whereas previous CA coloniza-
tion (OR 0.33; 95% CI 0.19–0.57; p <0.001) and previous
antibiotic use (OR 0.42; 95% CI 0.21–0.85; p 0.017) were
associated with CA candidaemia.
Discussion
In the general population of Barcelona, 48% of all cases of
candidaemia were caused by NAC. The distribution of Can-
dida species was generally similar to those reported from
other European countries, such as France and Italy [20,21],
with C. parapsilosis being the second most common Candida
spp. isolated. An exception is the incidence of C. glabrata,
which was the fourth most common species in the present
study, but the second most common in England and Wales
[22], Switzerland [23], Denmark [24] and the USA
[10,25,26]. An increase in the percentage of C. glabrata BSI
was ﬁrst reported in the USA during the 1990s [6,25,26].
However, this trend is not universal, and C. glabrata is less
common in other areas, including South America, Canada
and some European countries (e.g. Italy and France) which,
again, is in keeping with our results [20,21,27]. The changing
pattern of candidaemia may be attributable in part to the
large number of immunocompromised hosts and the wide-
spread use of prophylactic or empiric antifungal therapy [9],
although the role of widespread azole use in the emergence
of species other than CA as causes of candidaemia remains
controversial. Knowledge of the local epidemiological trends
in Candida species isolated in blood cultures is important to
guide the choice of empiric therapy.
Previous studies of risk factors for candidaemia due to
NAC compared to CA have focused on critically ill ICU
patients or patients with a haematological malignancy [14–
16,28] and have investigated a single species, such as C. par-
apsilosis or C. glabrata [8,14,29,30]. To our knowledge, the
risk factors for NAC vs. CA have not been prospectively
described in a general patient population.
The results obtained in the present study and those of
Chow et al. [15] contrast with the results reported by Shorr
et al. [16] who found no differences in the clinical character-
istics of ICU patients with BSI caused by NAC or CA. These
authors theorized that clinical variables do not allow one to
successfully predict the microbiology of fungaemia in a partic-
ular patient because NAC species are essentially endemic
[16]. Nonetheless, we found several differences in patients
with NAC fungaemia compared to those with CA: they were
signiﬁcantly younger, had a higher incidence of haematologi-
cal malignancies, were neutropaenic or had undergone hae-
matological transplantation, or had been exposed to
ﬂuconazole previously. NAC was not associated with an
increase in mortality or length of hospital stay compared to
CA, probably because C. parapsilosis accounted for a consid-
erable percentage of NAC isolates in our series, and this
species is known to be less virulent, more frequently associ-
ated with a CVC infectious origin, and uniformly susceptible
to ﬂuconazole [8,30].
Subsequent to multivariate analysis, NAC fungaemia was
found to be independently associated with having undergone
haematological transplantation (p 0.027). The potential risk
factors for developing NAC BSI identiﬁed in previous studies
have included neutropaenia and an underlying haematological
disease and, in these cases, C. tropicalis, C. krusei and even
C. glabrata were more prevalent [7,14,28]. Because it is a
general practice to use ﬂuconazole prophylaxis in high-risk
haematological patients, it is reasonable to conclude that
undergoing haematological transplantation could be a con-
founding risk factor, with previous ﬂuconazole exposure
being the determining predictor in these cases. Although
ﬂuconazole prophylaxis is associated with a reduction in the
incidence of candidaemia and attributable mortality, several
studies have investigated the way in which ﬂuconazole can
inﬂuence the development of azole resistance [9,31].
In our series, the predominant Candida species varied
according to the hospital care unit. C. parapsilosis was the
most prevalent species in the neonatal ICU (16 of 24 [67%]
cases), whereas CA was the most prevalent in surgical areas.
In our series, all except one case of NAC among neonates
were caused by C. parapsilosis. Considering that multivariate
analysis identiﬁed neonatal age as a risk factor for NAC, we
were able to determine that neonatal age is a predictor for
C. parapsilosis fungaemia. The association between neonatal
fungaemia and C. parapsilosis has been extensively described,
and some studies suggest that it may reﬂect the intensive
use of intravascular devices to treat neonates and children
[32,33].
We also found that ﬂuconazole exposure is a risk factor
for the development of NAC BSI. The results obtained in
the present study agree with the ﬁndings reported in previ-
ous studies postulating that widespread ﬂuconazole use
would result in selection of yeast species that are less sensi-
tive to this antifungal agent, such as C. krusei, C. glabrata and
C. tropicalis [9,15,31]. Fluconazole use and selection of ﬂuco-
nazole-resistant Candida spp. has been extensively described
in studies performed in ICU patients and in patients with
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cancer or haematological malignancies [3,30,31]. In patients
without cancer, the association between previous ﬂuconazole
exposure and NAC fungaemia is not as clear, with some
studies suggesting an independent relationship and others
failing to note this association [15,16,34]. Moreover, the
important percentage of C. parapsilosis, a yeast species that is
almost always susceptible to ﬂuconazole, is not explained by
the increase of ﬂuconazole use. It is likely that fungemia due
to C. parapsilosis reﬂects acquisition associated with the
widespread use of parenteral feeding and intravascular
devices [30–32].
We also found that patients were more likely to develop
CA fungemia if they had been treated previously with antibi-
otics at the onset of candidaemia or if they had been colo-
nized previously by CA. Previous antibiotic exposure has
been associated with CA in non-neutropaenic patients [34]
and previous Candida colonization by the same Candida spp.
has also been described as a risk factor for candidaemia [35].
The observations made in the present study are subject
to limitations. First, the data were obtained 6 years ago. Sev-
eral new treatment options subsequently have been devel-
oped (e.g. echinocandins and new triazoles) but, in all
probability, the epidemiology and species distribution of Can-
dida has not changed substantially, and these data are still
relevant. Second, only the presence or absence of risk factor
exposure was considered, and not the duration of exposure.
Because the study was not designed to quantify the length of
exposure, this variable is not available and any associated bias
cannot be assessed. Third, it may not have been appropriate
to pool all NAC species together because certain NAC spe-
cies are uniformly susceptible to ﬂuconazole. To address this
limitation, other studies [16] have analyzed C. krusei and
C. glabrata together vs. C. albicans, C. tropicalis and C. parapsi-
losis. However, the main goal of the present study was not
to investigate potential ﬂuconazole resistance but, instead, to
identify predictors of candidaemia due to NAC. Nonetheless,
the small number of ﬂuconazole-resistant isolates precluded
a risk factor analysis for individual Candida species. On the
other hand, some strengths of the present study include the
fact that risk factors for NAC fungaemia were examined in a
general population, the sample size is relatively large, and the
study design is prospective.
In summary, a number of factors were found to be inde-
pendently associated with an increased risk of candidaemia
due to NAC compared to CA. Neonatal age, having under-
gone haematological transplantation, and prior ﬂuconazole
use were associated with NAC BSI. Physicians can take these
speciﬁc characteristics into consideration when empiric
treatment with an antifungal agent must be started while
waiting for Candida species to be identiﬁed.
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